SCD Patients with a fully matched sibling donor (MSD) irrespective of the frequency or severity of symptoms MSD transplant can be considered. Parents/patient must be counseled as to the risks and benefits and provide their voluntary informed consent
Transfusion Dependent Alpha- or Beta- Thalassemia
Diamond Blackfan Anemia
Other Non-Malignant Hematologic Disorders
Karnofsky ≥ 60%, Lansky play score ≥ 60. Patients with lower performance score can be considered based on study team's evaluation.
Sexually active persons of childbearing potential or persons with partners of childbearing potential must agree to use a highly effective form of contraception during study treatment and for at least 4 months after the transplant.
You may not be if
Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 30 days of the start of treatment
HIV infection with a detectable viral load. All HIV+ patients must be evaluated by infectious disease (ID) and an HIV management plan established prior to transplantation.
Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted
Known allergy to any of the study components
Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study
Clareo Health | Allo HSCT for High Risk Hemoglobinopathies
